Table 6.

Incidence Proportions and Potentially Viable Systemic Options for Targetable Alterations in Non-small Cell Lung Cancer

Alteration	Incidence Proportion Among Non-small Cell Lung Cancer (Adenocarcinoma) in United States	Potential Therapeutic Agents
ALK rearrangements	4–5%	Alectinib, ceritinib, brigatinib, lorlatinib, crizotinib
BRAF V600E mutations	1–3%	Dabrafenib+trametinib
EGFR (common and uncommon mutations)	15–20%	Osimertinib, erlotinib, gefitinib, afatinib, dacomitinib
EGFR exon 20 insertion mutations	1–2%	Amivantamab
HER2 Exon 20 insertion mutations	1–3%	Trastuzumab, afatinib, ado-trastuzumab emtamsine, trastuzumab deruxtecan
KRAS G12C mutations	10–12%	Sotorasib
MET exon 14 skip mutations/high-level amplification	2–3%	Capmatinib, tepotinib, crizotinib
NTRK rearrangements	0–1%	Larotrectinib, entrectinib
RET rearrangements	1–2%	Selpercatinib, pralsetinib
ROS1 rearrangements	1–2%	Entrectinib, crizotinib, lorlatinib, ceritinib,